New HIV-vaccine tested on peopleFebruary 14, 2012
Actually, medical science can control an HIV-infection quite well, with a medicine cocktail. 'Seropositive' people (people who are infected with the HIV virus) now can lead a reasonably normal life, but their virus is not exterminated. When they stop the treatment it immediately rebounds.
Science knows what the problem is: the 'special forces' in our blood (the CD8 cells, in medical lingo) get not enough support from the general staff (the dendritic cells, that show the combat units what to attack). Dendritic cells exhibit on their exterior typical parts of the virus to be attacked. But human dendritic cells are not that good in getting the right information on the HIV virus and to transform it into good examples for the CD8 battle cells.
The virologists and HIV-physicians of the Institute of Tropical Medicine and the haematologists of Antwerp University Hospital have cooperated for years on that problem. Together they succeeded to 'load' dendritic cells of seropositive volunteers in the lab with the building instructions (genetic information in the form of so-called messenger RNA) for HIV proteins. They could make the dendritic cells to execute the instructions and to exhibit the resulting typical part of the HIV virus on their surface. Subsequent research in test tubes demonstrated that the 'loaded' dendritic cells were able to activate battle cells.
Time had come to proceed to humans. Flemish, Belgian and French research foundations provided grants. Six seropositive persons who for a long time already used the drug cocktails, were prepared to volunteer. The scientists filtered the dendritic cells from a large volume of their blood, cultivated them in test tubes in the cell-therapy unit of the Antwerp University Hospital and provided them with the genetic instructions of an HIV virus. They then froze the loaded cells.
The volunteers received four times, with four-week intervals, a small quantity of their own reworked dendritic cells. And indeed, after each vaccination the CD8 battle cells in their bodies recognised the virus better and better, while the vaccination had virtually no side effects. The most important result was that the vaccine-activated battle cells became better and better in suppressing the virus, in test tubes for the moment. But HIV remains a disguise artist; it still succeeds in changing its proteins sufficiently fast and often to let at least a few viruses escape the attack.
So it remains impossible to cure AIDS, but the results are encouraging: the vaccine, made of the participant's own dendritic cells, is safe and has some therapeutic effect, be it a limited one. But sufficiently strong for a publication in the most renowned journal for HIV researchers, AIDS. And more than sufficient to enthuse and motivate the Antwerp scientists.
Institute of Tropical Medicine Antwerp
Related HIV Vaccine Current Events and HIV Vaccine News Articles
Biomarker discovery may lead to new HIV treatment
Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine.
UNL team awarded $1.9M to develop new approach to HIV vaccine
Using a genetically modified form of the HIV virus, a team of University of Nebraska-Lincoln scientists has developed a promising new approach that could someday lead to a more effective HIV vaccine.
NIH grantees sharpen understanding of antibodies that may cut risk of HIV infection
What immune response should a vaccine elicit to prevent HIV infection?
New research on potent HIV antibodies
The discovery of how a KwaZulu-Natal woman's body responded to her HIV infection by making potent antibodies (called broadly neutralising antibodies, because they are able to kill multiple strains of HIV from across the world), was reported today by the CAPRISA consortium of AIDS researchers jointly with scientists from the United States.
Study of antibody evolution charts course toward HIV vaccine
In an advance for HIV vaccine research, a scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2.
Durable end to AIDS will require HIV vaccine development
Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic.
Animal vaccine study yields insights that may advance HIV vaccine research
A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research.
HIV-1 movement across genital tract cells surprisingly enhanced by usurping antibody response
Infectious disease researchers have identified a novel mechanism wherein HIV-1 may facilitate its own transmission by usurping the antibody response directed against itself.
HIV vaccines elicit immune response in infants
A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers, researchers at Duke Medicine report.
Scripps Research Institute Study Explores Barriers to HIV Vaccine Response
Researchers at The Scripps Research Institute (TSRI) discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins.
More HIV Vaccine Current Events and HIV Vaccine News Articles